Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial

Abstract Introduction Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-...

Description complète

Détails bibliographiques

Auteurs principaux:	Christopher J. Swearingen, Jeyanesh R. S. Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy, Yusuf Yazici
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2025-01-01
Collection:	Rheumatology and Therapy
Sujets:	CLK/DYRK inhibitor Disease-modifying osteoarthritis drug (DMOAD) Knee osteoarthritis Lorecivivint Osteoarthritis Safety
Accès en ligne:	https://doi.org/10.1007/s40744-024-00731-9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!